Literature DB >> 28988663

Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.

Li-Hsin Tsao1, Chih-Yi Hsin2, Hsin-Yi Liu3, Han-Chuan Chuang3, Li-Yuan Chen3, Yuarn-Jang Lee4.   

Abstract

BACKGROUND/
PURPOSE: The incidence of carbapenem-resistant Pseudomonas aeruginosa (CRPA) related healthcare-associated infection (HAI) has increased in recent year worldwide. This study is to investigate the risk factors associated with CRPA infections in a university hospital setting in Taiwan to provide more information for clinician and infection control system.
METHODS: A retrospective cross-sectional study was conducted from January 1st, 2009 to June 30th, 2014. Patients with P. aeruginosa related HAI were included and divided into the CRPA case group and carbapenem-susceptible Pseudomonas aeruginosa (CSPA) control group. The medical records were reviewed to identify risk factors for CRPA HAI and mortality. Patients with prior use of any anti-pseudomonal carbapenems were included in subgroup analysis.
RESULTS: 395 cases of P. aeruginosa infection were enrolled from total of 3263 HAI events; 63 were CRPA and 332 were CSPA. The prevalence of CRPA was 15.9% (63/395). Significant risk factors related to CRPA infection were longer time at risk, prior use of anti-pseudomonal carbapenems, and prior use of aminoglycoside (p < 0.05, 0.01, and 0.05). Furthermore, anti-pseudomonal carbapenem monotherapy did not significantly increase risk for CRPA infection.
CONCLUSION: The worldwide CRPA prevalence has been on the raise and Taiwan has been also keeping up with the trend. Antimicrobials usage should be monitored carefully, especially with carbapenems and aminoglycoside. Clinicians should be award of and understand about the risk of CRPA infection, which increases by 1% with each hospitalization day.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Carbapenem-resistant; Healthcare-associated infection; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2017        PMID: 28988663     DOI: 10.1016/j.jmii.2017.08.015

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  12 in total

1.  An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed?

Authors:  Thomas P Lodise; Sergey Izmailyan; Melanie Olesky; Kenneth Lawrence
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

2.  Antibiotic Resistance in Pseudomonas spp. Through the Urban Water Cycle.

Authors:  Anca Butiuc-Keul; Rahela Carpa; Dorina Podar; Edina Szekeres; Vasile Muntean; Dumitrana Iordache; Anca Farkas
Journal:  Curr Microbiol       Date:  2021-02-24       Impact factor: 2.188

3.  Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Authors:  Chih-Cheng Lai; Ying-Sheng Chen; Nan-Yao Lee; Hung-Jen Tang; Susan Shin-Jung Lee; Chin-Fu Lin; Po-Liang Lu; Jiunn-Jong Wu; Wen-Chien Ko; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2019-03-14       Impact factor: 4.003

Review 4.  Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms.

Authors:  Nan-Yao Lee; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Front Pharmacol       Date:  2019-10-04       Impact factor: 5.810

5.  Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016.

Authors:  Chun-Hsing Liao; Na-Yao Lee; Hung-Jen Tang; Susan Shin-Jung Lee; Chin-Fu Lin; Po-Liang Lu; Jiunn-Jong Wu; Wen-Chien Ko; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2019-03-04       Impact factor: 4.003

Review 6.  Bystander Selection for Antimicrobial Resistance: Implications for Patient Health.

Authors:  Valerie J Morley; Robert J Woods; Andrew F Read
Journal:  Trends Microbiol       Date:  2019-07-06       Impact factor: 17.079

Review 7.  Antimicrobial Resistance in Escherichia coli Strains Isolated from Humans and Pet Animals.

Authors:  Nikola Puvača; Rosa de Llanos Frutos
Journal:  Antibiotics (Basel)       Date:  2021-01-13

8.  Formulation and evaluation of injectable dextran sulfate sodium nanoparticles as a potent antibacterial agent.

Authors:  Osama A Madkhali; Sivakumar Sivagurunathan Moni; Muhammad H Sultan; Haitham A Bukhary; Mohammed Ghazwani; Nabil A Alhakamy; Abdulkarim M Meraya; Saeed Alshahrani; Saad Saeed Alqahtani; Mohammed Ali Bakkari; M Intakhab Alam; Mohamed Eltaib Elmobark
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

9.  Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Yanyan Hu; Yan Qing; Jiawei Chen; Congcong Liu; Jiayue Lu; Qi Wang; Shufang Zhen; Hongwei Zhou; Ling Huang; Rong Zhang
Journal:  Microbiol Spectr       Date:  2021-11-24

10.  Global Distribution Patterns of Carbapenemase-Encoding Bacteria in a New Light: Clues on a Role for Ethnicity.

Authors:  Claudio Neidhöfer; Christian Buechler; Guido Neidhöfer; Gabriele Bierbaum; Irene Hannet; Achim Hoerauf; Marijo Parčina
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.